Immune thrombocytopenia (ITP) has an incidence of approximately 2 to 4 per 100,000 person-years, with a bimodal age distribution that peaks after age 60 and continues rising past age 80, making it disproportionately a disease of the Medicare-age population. Because no single confirmatory test exists and antiplatelet antibody assays are positive in only 50 to 60 percent of patients, diagnosis rests on careful clinical exclusion, making etiology-specific documentation and accurate primary-versus-secondary classification essential to representing true clinical complexity.
AAVBC's Immune Thrombocytopenia Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering HCC/RAF V28 mapping, Medicare screening and surveillance, recognition of subtle early signs in older adults, diagnostic thresholds and classification, MEAT documentation standards, ASH 2019 guideline-aligned therapy escalation, medication safety, referral criteria, and coding specificity with case examples. Grounded in current ASH guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams distinguish primary from secondary ITP, document bleeding risk and etiology completely, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of immune thrombocytopenia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Immune thrombocytopenia (ITP) has an incidence of approximately 2 to 4 per 100,000 person-years, with a bimodal age distribution that peaks after age 60 and continues rising past age 80, making it disproportionately a disease of the Medicare-age population. Because no single confirmatory test exists and antiplatelet antibody assays are positive in only 50 to 60 percent of patients, diagnosis rests on careful clinical exclusion, making etiology-specific documentation and accurate primary-versus-secondary classification essential to representing true clinical complexity.
AAVBC's Immune Thrombocytopenia Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering HCC/RAF V28 mapping, Medicare screening and surveillance, recognition of subtle early signs in older adults, diagnostic thresholds and classification, MEAT documentation standards, ASH 2019 guideline-aligned therapy escalation, medication safety, referral criteria, and coding specificity with case examples. Grounded in current ASH guideline evidence, this guide supports consistent, individualized clinical decision-making, helping care teams distinguish primary from secondary ITP, document bleeding risk and etiology completely, and coordinate care with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of immune thrombocytopenia — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
